Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

Salivary Protease Inhibitor Exhibits Unique Anti-HIV


Reuters (08/06/97)

Merck researchers report in the August issue of Blood that the antiviral factor found in saliva, secretory leukocyte protease inhibitor (SLPI), significantly inhibits infection of monocytes by HIV-1. The inhibition apparently occurs prior to reverse transcription and independently of the compound's previously noted antiprotease activity. In vitro testing suggests that SLPI does not affect the virus directly, but the researchers suggest that "the inhibitory action is more likely due to interaction with the host cell." The researchers believe the compound "most likely inhibits a step of viral infection that occurs after virus binding but before reverse transcription."


Copyright © 1997 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in August 7, 1997. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.